Daniels J, Doukas P, Escala M, Ringbloom K, Shih D, Yang J, et al. Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. Nat Commun. 2020;11:1806 pubmed publisher

Mordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka A, Lalremruata A, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542:445-449 pubmed publisher

Beatson R, Parente Pereira A, Halim L, Cozzetto D, Hull C, Whilding L, et al. TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer. Cell Rep Med. 2021;2:100473 pubmed publisher

Poran A, Scherer J, Bushway M, Besada R, Balogh K, Wanamaker A, et al. Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. Cell Rep Med. 2020;1:100141 pubmed publisher

Ott P, Hu Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, et al. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020;183:347-362.e24 pubmed publisher

Ogongo P, STEYN A, Karim F, Dullabh K, Awala I, Madansein R, et al. Differential skewing of donor-unrestricted and γδ T cell repertoires in tuberculosis-infected human lungs. J Clin Invest. 2020;130:214-230 pubmed publisher

de Bruin R, Stam A, Vangone A, van Bergen en Henegouwen P, Verheul H, Sebestyen Z, et al. Prevention of V?9V?2 T Cell Activation by a V?9V?2 TCR Nanobody. J Immunol. 2017;198:308-317 pubmed

de Bruin R, Lougheed S, van der Kruk L, Stam A, Hooijberg E, Roovers R, et al. Highly specific and potently activating V?9V?2-T cell specific nanobodies for diagnostic and therapeutic applications. Clin Immunol. 2016;169:128-138 pubmed publisher